Bond Screener
Biogen
LEI W8J5WZB5IY3K0NDQT671
Organization name
Biogen Inc.
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Credit Ratings
in foreign currency
Public debt
6,567 mln USD
Upgrade to Premium features
Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market
Get access
-
Full access to the largest bond database
Bond parameters,
prospectuses -
Seamless
Data exportAnalyze the data in the most efficient way
-
Bond pricing
Current & historical quotes from 400+ stock exchanges & OTC market
-
Smart risk assessment
Credit ratings, financial reports
Trading Schedule Issuer map
Quotes
/
/
/
pcs.
pcs.
pcs.
- «
- 1
- ...
- {{ quotes.page - 2 }}
- {{ quotes.page - 1 }}
- {{ quotes.page }}
- {{ quotes.page + 1 }}
- {{ quotes.page + 2 }}
- ...
- {{ quotesLastPage }}
- »
Quotes provided by information providers are indicative in nature
Profile
|
Biogen Inc. is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company’s products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN.
|
General information
-
Organization nameBiogen Inc.
-
Organization statusOperating organization
-
Address133 Boston Post Road Weston, USA, 02493
-
Site
-
IR Site
News
IFRS/US GAAP reports
| 2026 | |
| 2025 | |
| 2024 | |
| 2023 | |
| 2022 | |
| 2021 | |
| 2020 | |
| 2019 | |
| 2018 | |
| 2017 | |
| 2016 | |
| 2015 | |
| 2014 | |
Show all
Hide
Authorization required
You need to request access
Stocks
General information
-
Organization nameBiogen Inc.
-
Organization statusOperating organization
-
Address133 Boston Post Road Weston, USA, 02493
-
Site
-
IR Site
Codes
-
LEIW8J5WZB5IY3K0NDQT671
-
SIC2836 BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
-
CIK0000875045
-
EIN33-0112644
